ANRO Stock — Alto Neuroscience, Inc.

Up next

Next earnings call

Oct 17, 2026 Est · unconfirmed · in 8 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 12, 2026

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 14.9 · calm Equity put/call 0.52

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +63%

above

Price vs 50-day avg +27%

above

RSI (14) 72

overbought

MACD trend Positive

52-week position 98%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +28%

trailing

6-month return +74%

trailing

YTD return +92%

this year

Relative strength +63%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $27 › 200d $21 — 50d above 200d

Institutional flow Accumulating

+4% holders QoQ · +26 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

8.24% of float · ▲ +4.5% MoM · 7.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

115 holders — near 2-yr high, broad support

Squeeze score 85

high risk · 0–100

Fundamentals

Strong

EPS growth +12%

Y/Y

Free cash flow $-51.8M

Balance sheet $159.7M

net cash

Quant / Vol

risk profile

Very High

Volatility 129%

annualized · 1-yr

Max drawdown −34%

past year

ATR 5.8%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy

1 · 2 · 4

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+63% Bullish

Price vs 50-day avg

+27% Bullish

RSI (14)

72 Bearish

MACD trend

Positive Bullish

52-week position

98% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $27 › 200d $21 — 50d above 200d

Institutional flow Accumulating

+4% holders QoQ · +26 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

8.24% of float · ▲ +4.5% MoM · 7.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

115 holders — near 2-yr high, broad support

Price context

position in its 52-week range

Range low $3 Now $34 · 98% Range high $35

vs 200-day avg +63% vs 50-day avg +27%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
cash, cash equivalents, and restricted cash	$244.2M	Q2 2026	—
Cohen's d on beta power	0.7	the quarter ended March 31, 2026	—
Cohen's d on Continuous Performance Task (sustained attention)	0.41	the quarter ended March 31, 2026	—
Cohen's d on gamma power	0.61	the quarter ended March 31, 2026	—
Cohen's d on individual alpha peak frequency	0.59	the quarter ended March 31, 2026	—
Cohen's d on theta power decrease	0.5	the quarter ended March 31, 2026	—
Cohen's d on theta-ITC versus placebo (cognitively impaired subgroup)	0.44	the quarter ended March 31, 2026	—
Cohen's d on theta-ITC versus placebo (overall study population)	0.34	the quarter ended March 31, 2026	—
Cohen's d on theta/beta ratio decrease	0.57	the quarter ended March 31, 2026	—
Percentage of patients in ALTO-300 MDD trial demonstrating ongoing compliance with underlying an	100%	the quarter ended March 31, 2026	—
Percentage of patients screened out of ALTO-100 trial through sponsor eligibility review process	11%	the quarter ended March 31, 2026	—
Percentage of patients screened out of ALTO-300 trial through sponsor eligibility review process	13%	the quarter ended March 31, 2026	—
Percentage of PK samples demonstrating expected drug concentration levels	97%	the quarter ended March 31, 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ANRO Alto Neuroscience, Inc. this stock	$1.34B	+92.4%	—	—	8.2%
ONC BeOne Medicines Ltd.	$557.05B	+21.5%	+22179.2%	856.5	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$136.93B	+19.2%	+46.2%	31.5	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$86.39B	+7.1%	+20.8%	20.8	3.3%
MRNA Moderna, Inc.	$69.62B	+352.1%	+4.3%	—	12.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

115

% held: 75.4%
Net QoQ: +2.3M sh
Top holder: Alpha Wave Global, LP

Held Float

View

Held by Funds

Fund positions

49

View

Short & Settlement

Short Interest Rising

Shares short

3.2M

Days to cover: 7.5d
Change: +138.4K sh

View

Short Volume

Short vol %

81%

As of: Aug 20, 2026

Short Total

View

Fails to Deliver

FTD shares

28.0K

Value: $780.1K
As of: Jul 28, 2026

View

Off-Exchange

Off-exchange %

51.6%

Week of: Jul 13, 2026

Off-exch Lit

View

Financials

Net income (FY)

$-63.2M

EPS diluted: $-2.19

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 12, 2026
This year: 14

View

Exempt Offerings

Offering

$50.0M

Filed: Oct 27, 2025

View

Earnings & Events

Earnings Calls

Last call

Jun 3, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
ANRO	+6.0%	+27.6%	+74.0%	+26.5%	+92.4%
SPY	-2.0%	+3.3%	+11.2%	+2.1%	+11.8%
vs SPY	+8.0%	+24.3%	+62.8%	+24.4%	+80.6%

ANRO · Alto Neuroscience, Inc.

Price & Indicators

Up next

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance